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Abstract
Multiple myeloma (MM) is an incurable haematological malignancy affecting approximately 7:100,000 people. Mono-
clonal gammopathy of undetermined significance (MGUS) and ‘smouldering’ MM precede symptomatic MM. Cytogenet-
ics in MM is the most powerful prognostication tool incorporated into different classifications, including the Revised 
International Staging System (R-ISS) and the Mayo Clinic Risk Stratification for Multiple Myeloma (mSMART). Methods 
commonly used to test for cytogenetic aberrations include conventional karyotyping and fluorescence in situ hybridisa-
tion (FISH), although the difficulty of obtaining metaphases in plasma cells results in low yields.
Therefore, new genomic tools are essential to explore the complex landscape of genetic alterations in MM. These in-
clude next generation sequencing, a highly sensitive method to monitor minimal residual disease. The serial evolution of 
MGUS to MM is accompanied by a range of heterogenous genetic abnormalities, divided into primary (involving mostly 
chromosome 14 translocations and trisomies) and secondary genetic aberration events (involving mostly 17p, 1p, 13q 
deletions, 1q gain, or MYC translocations). Based on the primary genetic aberration results, strong prognostic features 
of MM have been identified with distinct clinical characteristics. High risk aberrations include 17p deletion, t(4;14), 
t(14;16), t(14;20) and chromosome 1 abnormalities. The incorporation of novel drugs and maintenance strategies in 
conjunction with autologous stem cell transplantation partially overcome the adverse effect of some of these genetic 
aberrations. Nonetheless, survival remains worse in this group compared to standard risk patients. Clinical decisions 
regarding treatment should be based on the cytogenetic results. The establishment of individualised and mutation-
-targeted therapies are of the greatest importance in future studies.
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Introduction
Multiple myeloma (MM) is a neoplastic plasma cell disor-
der which affects approximately seven in every 100,000 
people, giving it the second highest incidence among all 
haematological malignancies in the Western world [1–3]. 
MM is preceded by a pre-malignant stage called monoc-
lonal gammopathy of undetermined significance (MGUS), 
which is present in over 3% of the population >50-years-
-old, and the incidence increases with age [4]. The risk 
of progression of MGUS to MM is approximately 1% per 
year depending on prognostic features (e.g. paraprotein 
concentration, immunoglobulin isotype and free light chain 
ratio) [5]. While MGUS is a ‘benign precursor state’ which 
is devoid of any myeloma defining events (MDE), MM can 
cause severe symptoms and end-stage organ damage 
including renal insufficiency (present in 20% of newly 
diagnosed patients), anaemia (haemoglobin <12 g/dL 
present in 73% of patients), skeletal lesions (present 
in approximately 65–75% of patients) or hypercalcemia 
(calcium level >11 mg/dL present in 13% of patients) [6]. 
According to the updated International Myeloma Working 
www.journals.viamedica.pl/acta_haematologica_polonica 19
Sarah Goldman-Mazur et al., Cytogenetic and molecular aberrations in multiple myeloma
how these subclones emerge, how they are selected and 
what is their prognostic implication, need to be investiga-
ted in future studies.
In general, the pathogenesis of MM can be visualised 
by two steps: the establishment of MGUS and progression 
from MGUS to MM (Figure 1) [14]. This process is accompa-
nied by different cytogenetic changes (Table II). The evolu-
tion of MGUS is thought to be a result of abnormal antigen 
stimulation and is caused by primary cytogenetic aberra-
tion events, so-called ‘disease-initiating’ aberrations. The 
primary cytogenetic abnormalities help to classify MGUS 
and MM into several subtypes and consist mostly of tri-
somies and translocations involving chromosome 14 [5]. 
Additionally, primary cytogenetic abnormalities are mostly 
non-overlapping [15]. The second step occurs rather due 
to random cytogenetic mutations (called secondary cytoge-
netic aberration events) resulting in the evolution to symp-
tomatic MM and further MM progression [16]. Secondary 
cytogenetic aberrations might overlap, and are typically 
subclonal (Figure 1) [5].
This review provides an overview of the different cyto-
genetic approaches used to stratify MM patients. We will 
discuss cytogenetic and molecular aberrations, their fre-
quency, and clinical and prognostic implications.
Laboratory testing strategy
Conventional cytogenetics  
(G-band karyotyping)
Conventional cytogenetics is a well-established and univer-
sally available test, and it also provides a whole genome 
analysis at once. On the other hand, the detection of chro-
mosomal abnormalities using conventional cytogenetics is 
limited due to low proliferative activity of malignant plasma 
cells and low number of plasma cells in an often haemodilu-
ted bone marrow aspirate. Chromosomal abnormalities 
are detected in only 30% of patients without CD138+ cell 
enrichment [17]. In plasma cell leukemia, cytogenetic 
aberrations are more common (up to 68% of cases) [18]. 
Despite this limitation, karyotyping provides essential 
Group (IMWG) criteria, the diagnosis requires ≥10% clonal 
bone marrow plasma cells or a biopsy-proven plasmacy-
toma plus evidence of one or more MDE included in the 
SLiM-CRAB acronym (Table I) [7]. However, unlike other 
haematological malignancies, no specific cytogenetic 
pathognomonic criterium for MM exists.
The disease is considered incurable, and survival may 
vary from a few months to over 15 years; this diversity is 
most strongly driven by the genetic abnormalities present 
in the plasma cells [8].
In the era of modern drugs including proteasome inhibi-
tors (PIs) (bortezomib/carfilzomib/ixazomib), immunomodu-
latory drugs (IMIDs) (thalidomide/lenalidomide/pomalido-
mide), monoclonal antibodies (daratumumab/isatuximab/ 
/elotuzumab), and antibody drug conjugates (belantamab 
mafodotin), median overall survival reaches 6+ years [9].
Several features affect survival: host characteristics, 
tumour burden and biology (cytogenetics) as well as the 
response to treatment. Laboratory risk factors for a poorer 
prognosis have been identified, including serum beta2-mic-
roglobulin (β2M), low albumin and/or elevated lactate de-
hydrogenase. However, genetic changes seem to play the 
largest role in prognosis in MM [10].
Studying myeloma genetics has been always limited 
due to low proliferation potential of the plasma cells for 
standard karyotype analysis. Nonetheless, in recent years 
the development of genetic tools including microarrays and 
next-generation sequencing (NGS) has led to substantial 
progress in understanding the genetics of MM [11].
MM remains a highly heterogenous and complex 
disease with varied genetic aberrations resulting in mul-
tiple subclones. A major clone dominates throughout the 
disease course, although minor clones may evolve and be 
responsible for chemoresistance or serve as a reservoir 
for relapses or progressions [11, 12]. Interestingly, in a re-
cent study by Merz et al., the presence of subclones was 
prognostic for smouldering MM to transform into MM; ho-
wever, the risk of progression was not constant and chan-
ged due to clonal evolution [13]. Nonetheless, the mecha-
nism and driving factors resulting in the development of 
Table I. For diagnosis of multiple myeloma, the criterium of clonal bone marrow plasma cells ≥10% or biopsy-proven bony or extramedul-
lary plasmacytoma should be met, and any one or more of the following myeloma-defining events (SLiM CRAB) should be present
Calcium Hypercalcemia: serum calcium >0.25 mmol/L (>1 mg/dL) higher than upper limit of normal or >2.75 mmol/L 
(>11 mg/dL)
Renal Insufficiency Renal insufficiency: creatinine clearance <40 mL per minute or serum creatinine >177 μmol/L (>2 mg/dL)
Anaemia Anaemia: haemoglobin value of >2 g/dL below lower limit of normal, or haemoglobin value <10 g/dL
Bones Bone lesions: one or more osteolytic lesions on skeletal radiography, computed tomography (CT), or positron 
emission tomography-CT (PET-CT)
Sixty Clonal bone marrow plasma cell percentage ≥60%
Light chains Involved: uninvolved serum free light chain (FLC) ratio ≥100 (involved free light chain level must be ≥100 mg/L)
Magnetic resonance >1 focal lesion on magnetic resonance imaging (MRI) studies (at least 5 mm in size)
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information on numerical and structural chromosomal 
changes. Numerical aberrations include hyperdiploidy or 
non-hyperdiploidy, whereas structural abnormalities inclu-
de translocations or copy number aberrations (i.e. deletions 
or gains). Furthermore, conventional karyotyping is an inde-
pendent prognostic factor even in the era of modern testing 
modalities [e.g. fluorescence in situ hybridisation (FISH), 
NGS, and gene-expression profiling (GEP)], and should be 
routinely performed as an initial diagnostic workup espe-
cially in situations where a FISH test is unavailable [19, 20].
FISH analysis
FISH testing is based on the use of fluorescent probes that 
bind to highly complementary nucleic acid sequence. Using 
a variety of FISH probes, numerous genetic alterations 
might be detected, including numerical amplifications or 
deletions, structural rearrangements and translocations 
[21]. On conventional cytogenetics, in patients with com-
plex karyotype, some aberrations (e.g. translocations) are 
cryptic, and FISH enables their detection [22]. Furthermore, 
a FISH test does not depend on the proliferation rate, and 
the probes can be applied on nondividing cells, mainly on 
interphase cells [21]. However, the detection sensitivity is 
limited by the number of plasma cells in the whole bone 
marrow, which is especially low in patients after treatment 
or early in the diagnosis or relapse (when plasma cells ran-
ge from 1–20%) [23]. Consequently, FISH is run mainly on 
CD138+ enriched cells, and different techniques are used 
to target and enrich the monoclonal plasma cells, e.g. im-
munostaining (cytoplasmic immunoglobulin FISH, cIg-FISH), 
Table II. Genetic abnormalities in multiple myeloma, their frequency and clinical impact
Cytogenetic abnormalities Frequency [%] Clinical impact, additional characteristics
Primary
t(4;14)(p16;q32) 10–15 Adverse, good response to proteasome inhibitors, unfavourable for any 
immunomodulatory drug
t(6;14)(p21;q32) 2 Neutral




Hyperdiploidy 50 Favourable, good response to lenalidomide in patients with trisomies
Secondary
13q deletion 45–50 Adverse
MYC translocation 15–20 Neutral or adverse
1q21 gain 35–40 Adverse, might be implicated in bortezomib resistance
1p32 deletion 30 Adverse
17p deletion At diagnosis <10,  
at relapses >30%
Adverse, possible central nervous system involvement, pomalidomide 
seems to be beneficial
Figure 1. Cytogenetic abnormalities in multiple myeloma (MM) (modified from [14]); amp — amplification; del — deletion; IgH — immunoglobu-
lin heavy chain; MGUS — monoclonal gammopathy of undetermined significance; SMM — smoldering multiple myeloma; t — translocation
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selection by magnetic cell sorting (MACS), fluorescence-
-activated cell sorting (FACS), as well as targeted manual 
scoring or customised automated image analysis [24].
The European Myeloma Network (EMN) guidelines re-
commend that at least 100 cells should be scored when 
analysing FISH [23]. The cut-off value for positivity remains 
a controversial issue and varies from laboratory to labora-
tory; there is no uniform criterion. It is related to the tes-
ting strategy and the various ways to establish cut-off for 
different FISH patterns in different laboratories [25, 26]. 
It is recommended by the EMN to use conservative cut-off 
levels: 10% for fusion or break-apart probes and 20% for 
numerical abnormalities [23], although in clinical practice 
the threshold for a positive test is very often much lower.
Molecular methods
Although not used in daily clinical practice outside clinical 
trials, advanced oncogenomic analyses are very impor-
tant tools to understand the complex genetic landscape, 
and hence clinical outcomes, of MM patients. Different 
genomic analysis methods exist to research into the vari-
ous processes of translating the genomic information. The 
most comprehensive test, NGS, is a process that allows the 
determination of the sequence of nucleotides in a section 
of DNA. This provides a full, integrated spectrum of gene 
mutations, aneuploidies, segmental copy-number changes 
and translocations. Utilising NGS has identified several 
recurrent gene mutations in newly diagnosed MM patients, 
including the most common mitogen activated protein ki-
nase (MAPK) pathway, NF-κB pathway and TP53 pathway 
genes [27]. Although NGS is not yet universally available, in 
the future it will be an important tool in the diagnosis and 
monitoring of the minimal residual disease (MRD) due to 
its high sensitivity [28]. Of note, large sequencing studies 
in MM are being conducted to determine the relevance of 
different mutations, and preliminary results are promising 
(CoMMpass, The Myeloma Genome Project) [29, 30]. The 
GEP analyses the RNA expression of different genes perti-
nent to different functions [31]. It is an important marker 
to detect high risk patients (Table III) [32], and it also helps 
to establish classifiers for prognostication in addition to 
the International Staging System (ISS) or FISH known high 
risk factors [33]. Several genes lists have been found to 
have strong prognostic information, including commercially 
available GEP70 and SKY92 profiles [32, 34]. A single- 
-nucleotide polymorphism (SNP)-microarray is a technique 
of the hybridisation of fragmented single-stranded DNA to 
arrays containing hundreds of thousands of unique nucleo-
tide probe sequences. SNP is the smallest genetic variation 
that can occur within a DNA sequence. SNP microarray can 
detect small copy number changes such as gene deletion, 
chromothripsis, complex copy number changes, and am-
plification, as well as copy neutral loss of heterozygosity 
(CN-LOH), which is an important oncogenic event [25]. It 
also detects aberrations in small populations (subclones) 
due to clonal evolution [25], of which the most common 
are complex MYC 8q24 rearrangements or amplifications, 
1q gain, 1p and 17p deletions [35, 36].
Using the genomic tools, several molecular classifica-
tions have been established in MM. They have been also 
incorporated into well-known staging systems to more pre-
cisely estimate an individual patient’s disease risk and cli-
nical outcome. Incorporating the novel molecular methods 
into clinical use and establishing personalised therapies ba-
sed on the molecular findings will be of the utmost urgency.


















Stage I ISS I, standard risk by FISH (no 
high-risk chromosomal abnor-
malities) and normal LDH
Stage II Neither R-ISS I nor III
ISS III, either high risk by FISH 
[del(17p) and/or t(4;14) and/or 























High plasma cell S-phase (cut-off 
varies)
GEP: high risk signature
Double-hit: any two high-risk 
factors





Presence of alterations detected 
by: UAMS, Skyline 92–HOVON, 
IFM
β2M — beta2 microglobulin; FISH — fluorescence in situ hybridisation; GEP — gene expression 
profiling; LDH — lactate dehydrogenase





Hyperdiploidy, commonly involving gain of odd-numbered 
chromosomes (trisomies), is detected in approximately 
50% of patients with MM [5, 37]. Trisomies 3 and 5 are 
known to improve overall survival, but trisomy 21 impairs 
overall survival [38]. Patients with trisomies have particu-
larly good response to IMIDs [39]. In approximately 10% 
of patients, trisomies and IgH translocations coexist [37]. 
The prognostic impact of this coexistence is a matter of 
controversy. Kumar et al. reported the presence of trisomies 
in patients with high risk translocations, namely t(4;14), 
t(14;16), t(14;20), or TP53 deletion, treated with modern 
drugs (PI and IMiD- based regimens). The adverse impact 
associated with these prognostic markers was partially 
ameliorated [37]. In contrast, Pawlyn et al. showed that in 
high risk cytogenetic patients coexistent hyperdiploidy did 
not abrogate a poor prognosis, although the patients were 
treated with older conventional drugs (cyclophosphamide 
with thalidomide and dexamethasone, or with vincristine) 
[40]. Hyperdiploidy is often accompanied by other struc-
tural chromosome changes (e.g. translocations, deletions 
or duplications) and a hyperdiploid karyotype with ≥2 of 
those aberrations should be considered as an independent 
high risk factor [41].
Non-hyperdiploidy
Non-hyperdiploidy is defined as hypodiploid, pseudodiploid, 
and near-tetraploid karyotypes. Hypodiploidy is defined 
as having ≤44 chromosomes in a cell, pseudodiploidy as 
having 45–46 chromosomes in a cell, and near-tetraploid 
karyotype originates from doubling of the hypodiploid and 
pseudodiploid karyotypes (>75 chromosomes) [42]. Hy-
podiploidy was an important independent factor for worse 
overall survival in multivariate analysis that included Durie 
and Salmon stage, treatment or bone marrow plasmocy-
tosis [43]. In the non-hyperdiploid population, hypodiploid 
cases are associated with a higher prevalence of genetic 
alterations and a worse prognosis [42].
IGH translocations
IGH translocations, with a breakpoint on chromosome 14 
band q32, are often present in tumours of the lymphoid line-
age due to the common physiological DNA rearrangements at 
the immunoglobulin heavy chain (IGH) locus that might have 
been displayed incorrectly [44]. The aberration in IGH in MM 
occurs mostly during class switching, and the juxtaposition of 
an oncogene next to the IGH locus results in overexpression 
of the affected oncogene [45]. In MM, the IGH translocations 
occur in up to 60% of patients [15, 46]. There are five main 
translocation partner chromosomes including the t(4;14)
(p16;q32) — multiple myeloma set domain (MMSET), t(6;14)
(p21;q32) — cyclin D3 gene, t(11;14)(q13;q32) — cyclin D1 
gene, t(14;16)(q32;q23) — musculoaponeurotic fibrosarco-
ma (C-MAF), and t(14;20)(q32;q12) — musculoaponeurotic 
fibrosarcoma oncology family, protein B (MAFB) [45]. Moreo-
ver, the recurrent IGH translocations (mostly with partner 
chromosomes 11, 4, and 16) are highly associated with 
nonhyperdiploid karyotype [47].
t(4;14)(p16;q32)
Translocation t(4;14), present in 10–15% of newly diagno-
sed cases, is not detectable by conventional karyotyping 
[25, 48, 49]. It is associated with poor prognosis and is con-
sidered to be a high-risk prognostic factor [48, 49]. Trans-
location t(4;14) is associated with immature morphology, 
higher tumour mass, and more frequent chromosome 13 
abnormalities [50]. It is also reported to be less frequently 
associated with bone lesions, which consequently might 
be associated with delayed diagnosis [51]. Patients with 
t(4;14) seem to benefit from bortezomib-based therapy and 
bortezomib maintenance, and lenalidomide maintenance 
also might provide better survival in this group of patients 
[52, 53, 54]. It is also recommended to implement autolo-
gous stem cell transplantation (ASCT) as soon as possible 
in this cytogenetic subtype, and tandem ASCT should be 
considered [5]. Moreover, data from the MM-003 trial 
shows that pomalidomide plus low-dose dexamethasone 
is an effective strategy in relapsed/refractory settings in 
patients with t(4;14) [55].
t(11;14)(q13;q32)
The most common IGH translocation, accounting for 15– 
–20% of cases, is t(11;14) [48, 49, 56]. This translocation 
results in upregulation and overexpression of the cyclin 
D1 that might be detected by immunohistochemistry [57]. 
Translocation t(11;14) is more prevalent in plasma cell leu-
kemia patients as well as in light chain amyloidosis patients 
than in MM patients [58, 59, 60]. Although the prognostic 
impact is considered to be standard, some studies suggest 
that the overall survival and response rates are inferior to 
other standard risk patients [61, 62]. Translocation t(11;14) 
is more frequent among the African-American population 
and exerts negative influence on the survival in African-
-Americans compared to non-African-Americans [63, 64]. 
It is associated with lymphoplasmacytic morphology and 
frequently with low serum monoclonal protein or nonsecre-
tory MM, and it is also less likely to coexist with hyperdiploid 
karyotype [50, 57]. In t(11;14) the expression of CD20 is 
often present [65]. The Mayo Clinic experts recommend the 
use of combined bortezomib and lenalidomide regimens 
followed by early ASCT and lenalidomide maintenance 
in t(11;14) patients [5]. The t(11;14) is associated with 
high expression of BCL2 protein and several studies have 
suggested the efficacy of the use of venetoclax, the BCL2 
inhibitor, in t(11;14) positive patients. 
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t(14;16)(q32;q23)
The more common MAF translocation, t(14;16), present 
in 2–5% of newly diagnosed cases, is hardly detectable 
by conventional karyotyping [25, 49, 56]. Translocation 
t(14;16) is associated with adverse outcomes, even in the 
era of novel drugs, something recently confirmed by a large 
international sample study conducted by our group [49, 66, 
67]. Renal failure as a MDE is more frequently observed 
in patients with t(14;16) than in other cytogenetic subty-
pes. It is associated with high levels of free light chain in 
serum, which might partially explain the poorer prognosis 
in t(14;16) positive group of patients [51, 68]. It has been 
observed that t(14;16) is associated with negativity in 
CD56 expression and high proliferative activity, which might 
predispose toward an adverse outcome [69]. According to 
the Mayo Clinic experts, the treatment approach should be 
similar as in t(4;14), and in patients with renal failure it is 
recommended to combine bortezomib with cyclophospha-
mide, thalidomide or adriamycin over lenalidomide [5]. Our 
study suggests that at least a three-drug induction regimen 
(including IMID and PI) should be used, ASCT should be 
performed wherever possible [67, 68], and tandem ASCT 
should be considered [5]. Maintenance should be based 
on bortezomib [5].
t(14;20)(q32;q12)
The second MAF translocation, t(14;20), has a low preva-
lence, 1%, and also exhibits adverse impact on outco-
mes, comparable to t(14;16) [56, 70, 71]. Translocation 
t(14;20) is also associated with higher frequency of renal 
failure due to high levels of free light chains in serum [51, 
68]. Treatment based on PI should be used in an induction 
therapy [68]. Double ASCT should be considered as an 
upfront treatment strategy in this group of patients [70], 
and maintenance should include bortezomib [5].
Secondary cytogenetic abnormalities
MYC translocation
MYC translocations are secondary events and occur at late 
stages of tumour progression. They are present in 15–20% 
of patients [48, 72]. Most MYC translocations involve IGH 
locus, however other genes might be also involved (IGL, 
IGK, FAM46C, FOXO3 or BMP6) [56]. As a result of the 
juxtaposition, the expression of c-MYC is increased [73]. 
The impact of MYC translocation on survival is believed to 
be negative, although it is still a matter of debate [73, 74]. 
It has been suggested that the negative impact on outcome 
of MYC is restricted to hyperdiploid MM and is caused by an 
interaction between t(MYC) and gain of 1q21 [72].
1q gain
1q gain is one of the most common aberrations in MM, 
present in approximately 30% of patients [75]. It is asso-
ciated with end-organ damage and a higher tumour burden 
[75]. It has been shown that 1q gain is associated with the 
evolution from MGUS to MM, and the copy number of the 
1q gain increases with disease progression [76]. Although 
the prognostic impact is a contentious issue, recent studies 
suggest that 1q gain has a strong, independent negative im-
pact on survival, even in the era of modern drugs and ASCT 
[75, 77]. Although neither IMID- and PI-based treatment 
regimens nor ASCT seem to prolong survival in patients 
with 1q gain, a recent Mayo Clinic study suggested that 
PI-based strategies might show a slightly better effect on 
outcomes [75]. Nonetheless, another study showed that 
with increasing number of copies of 1q gain, bortezomib 
resistance also increases [78].
1p deletion
1p deletion is present in approximately 20% of patients 
and has an adverse impact on outcomes [79, 80]. These 
patients might need more intensive treatment, similar to 
that for other high-risk MM subtypes [5, 80].
13q deletion
13q deletion is present in 45–50% of patients with MM 
[48]. The 13q deletion often coexists with other cytogenetic 
abnormalities, and the presence and time of occurrence 
of 13q deletion depends on the presence of specific 
concurrent abnormalities [81]. 13q deletion detected by 
conventional karyotyping appears to predict poor outcomes 
(present in 10–15% of newly diagnosed patients) [82]. 
It has been shown that bortezomib might overcome the 
adverse impact of 13q deletion [83].
17p deletion
17p deletion (associated with loss of the TP53 gene) 
is present in 10% of newly diagnosed patients, and the 
incidence increases with disease progression [48, 56]. 
It is present in the majority of cases of plasma cell leu-
kemia [84]. 17p deletion is considered to be the most 
detrimental prognostic factor of high-risk disease and 
a poor outcome [66, 71]. The size of clone carrying the 
abnormality seems to be significant for the prognosis, 
although a recent study found contradictory results [85]. 
The bi-allelic inactivation of TP53 has an additional negati-
ve impact on survival [86]. TP53 deletions are associated 
with more aggressive disease course and complications 
including plasmocytomas and hypercalcemia [49]. The 
studies on the influence of different treatment strategies 
are inconsistent. BMT CTN 0702 trial results showed no 
survival benefit of either tandem ASCT or intensive treat-
ment that included ASCT with a subsequent four cycles 
of bortezomib and lenalidomide followed by lenalidomide 
maintenance in patients with 17p deletion [87]. Moreo-
ver, Lakshman et al. showed that a deletion 17p positive 
patient did not benefit from IMID plus PI-based induction 
as well as early ASCT [85]. On the other hand, according 
Acta Haematologica Polonica 2021, vol. 52, no. 1
www.journals.viamedica.pl/acta_haematologica_polonica24
to the recent study based on the EMN02/HO95 trial, 
patients with 17p deletion were benefiting from intensive 
treatment including tandem ASCT and bortezomib-based 
induction therapy [88].
Despite all these differences, recommendations sug-
gest using induction therapy based on IMIDs and PI (bor-
tezomib or carfilzomib) and subsequently considering tan-
dem ASCT and prolonged bortezomib maintenance [71, 
89]. Of note, pomalidomide seems to be particularly active 
in 17p deletion [90].
Specific mutations
In recent years, the genomic landscape of MM has been tho-
roughly studied, and several recurrent mutations identified, 
most of them involving genes implicated in the translocation 
of chromosome 14 or MAPK pathway, critical in cell growth 
and survival [91]. Some of them are related to the cytogene-
tic MM subtype, e.g. FGFR3 or PRKD2 genes mutations occur 
mainly in t(4;14) positive patients; CCND1, KRAS and IRF4 
genes mutations are detected in t(11;14) positive patients 
or TP53 gene mutation is present in 17p deletion positive 
patients [5]. The MAPK genes mutations are represented by 
KRAS and NRAS, present in 40% of patients as well as BRAF 
genes mutations present in approximately 4% of patients 
[92]. Patients with mutations in NRAS or KRAS have worse 
survival than those with wild-type RAS genes [93]. It has been 
shown that patients with NRAS mutation exhibit reduced 
sensitivity to bortezomib [94]. For the MAP kinase pathway, 
several mutation-specific drugs are tested, e.g. vemurafenib 
in BRAF positive tumours or trametinib in AKT mutation [5].
Double/triple hit MM
High risk cytogenetic aberrations, especially secondary 
genetic aberration events, often overlap. For example, in 
a study by Boyd et al. in a group of patients with adverse 
IGH translocation [t(4;14), t(14;16) or t(14;20)], almost 
72% had additionally 1q gain, and 12.4% had 17p deletion 
[95]. To address the prognosis of patients with multiple 
adverse cytogenetic aberrations, the mSMART classification 
includes the concepts of ‘double hit’ (when any two high 
risk factors are present) and ‘triple hit’ (when any three 
high risk factors are present) as a high risk stage with 
poor prognosis (Table III) [7]. A recent study showed the 
predictive value of double- and triple-hit MM, with double-
-hit MM having OS of 6 months vs. 32 months for patients 
with one high risk factor, and 57 months for patients with 
no high risk factor [96].
Staging approaches
The most universally accepted staging systems are set out 
in Table III. The Mayo Clinic recommends both conventional 
cytogenetic and FISH tests, and FISH is preferred if both are 
not available. All patients should be stratified and classified 
into standard- or high-risk groups using the mSMART criteria 
(Table III) and the FISH set should include detecting at least 
t(11;14), t(4;14), t(14;16), t(6;14), t(14;20), trisomies, and 
17p deletion [71, 97]. The EMN recommends performing 
FISH after CD138+ plasma cell enrichment, and the analysis 
should include at least t(4;14) and 17p deletion; analysis 
of t(14;16), 1q gain and 1p deletion [98]. The National 
Comprehensive Cancer Network (NCCN) recommends FISH 
panel on bone marrow which includes 13 deletion, 17p 
deletion, t(4;14), t(11;14), t(14;16), t(14:20), 1q amplifica-
tion and 1p deletion as an initial work-up [99]. According 
to the IMWG, the essential testing should include either 
cIg-FISH or FISH carried out on the nuclei from purified 
plasma cells. The minimum panel required for prognostic 
estimation should include t(4;14), t(14;16) and 17p dele-
tions. A more comprehensive panel should include testing 
for t(11;14), 13 deletion, ploidy category and chromosome 1 
abnormalities [100]. The Polish guidelines for the basic 
evaluation of cytogenetic prognosis suggest stepwise FISH 
testing: the first step includes TP53 gene and IGH gene. 
If the IGH rearrangement is present, gene FGFR3/t(4;14) 
should be verified. If there is no FGFR3 fusion, further 
analysis should include MAF/t(14;16) gene status. Exten-
ded testing should include additionally t(14;16), t(14;20), 
chromosome 1 status, t(11;14), MYC rearrangement, 
13 de letion and the 5, 9 and 15 chromosome aberrations. 
Karyotyping is an optional study according to the Polish 
experts’ recommendations [101].
It should be highlighted that the risk factors described 
for newly diagnosed patients might be applicable to the 
relapse or refractory setting. However, in that case, other 
factors seem to be equally crucial. For example, the resi-
stance to primary treatment (primary refractory patients), 
or a short response after first line treatment with ASCT 
have poor prognosis, even if other high risk factors were 
not detected [102, 103]. Another powerful predictor of 
outcome in MM is MRD status after induction treatment, 
and its negativity predicts better survival [104]. Although 
not routinely monitored, MRD has a growing significance 
in monitoring the disease in clinical trials. MRD can be 
monitored by multiparameter flow cytometry or using mo-
lecular techniques like polymerase chain reaction (PCR) 
or NGS on a bone marrow sample. Studies evaluating NGS 
in MRD have shown that its negativity surpasses the tra-
ditional complete remission criterium in predicting better 
outcomes in MM patients [105, 106], and its sensitivity re-
aches 10–6 [107]. Limitations in utilising NGS in MRD moni-
toring include lack of standardisation, low availability, and 
frequent haemodilution of the bone marrow sample [98].
Conclusions
MM is a highly heterogenous, gnomically evolving and 
ever-changing disease, with no disease-identifying unique 
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molecular aberration. The coexisting numerous subclones 
and potential lack of functionality of some mutations 
make interpretation even more difficult. Nonetheless, 
based on the cytogenetic and molecular landscape, 
several different subtypes of MM have been identified 
with different clinical characteristics and prognosis, and 
clinical decisions regarding treatment should be made 
based on the cytogenetic results. The establishment of 
individualised and cytogenetic subtype- or mutation-tar-
geted treatment strategies are of the utmost importance 
in future studies.
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